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Platycodin D, extract from the root of Platycodon grandiflorum, is one of the most
important monomers of the Qinbaiqingfei pellets (Qinbai) that has already been approved
as the first Traditional Chinese Medicine for clinic use as an anti-M. pneumoniae
agent. Qinbai constituents Scutellaria baicalensis and Platycodon grandiflorum were
used to treat thousands of patients clinically in China each year. In this study, a
M. pneumoniae–infected mouse strain, BALB/c, and a human-derived epithelial cell line,
A549 type II pneumocytes, were used as experimental model. Anti-M. pneumoniae
effect of Platycodin D was measured by the Real-time quantitative PCR, while the cell
pathological change with hematoxylin and eosin and the growth recovery effects were
determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Trypan
Blue dye in the experimental model after M. pneumoniae infection. Our research results
showed that Platycodin D could significantly inhibit M. pneumoniae and promote cell
growth after anti- M. pneumoniae treatment in the infected cells or mice.
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INTRODUCTION
Mycoplasma pneumoniae (M. pneumoniae) is the common
pathogen for a variety of respiratory infections among school-
age children. It is also a leading cause of all community-acquired
pneumonia and other acute or chronic airway diseases (Waites
and Talkington, 2004).
Because of M. pneumoniae’s lack of cell wall, most antibiotics,
including penicillin, are not effective in treating M. pneumoniae
infections. Macrolides are still the most efficient drugs in treat-
ing M. pneumoniae infections due to their strong antimicrobial
and anti-inflammatory properties. Themechanism ofmacrolides’
antimicrobial action is the inhibition of bacterial protein syn-
thesis after Macrolides are reversibly bound to the P site of the
50S subunit of the bacterial ribosome leading to the inhibi-
tion of polypeptide chain elongation and ribosomal translocation
(Wikipedia, 2011).
Qinbai, a drug extracted from natural sources including
Scutellaria baicalensis and Platycodon grandiflorum, is the first
Chinese Traditional Medicine clinically used in treatingM. pneu-
moniae infections in China. Qinbai phase II and III trials with 653
patients enrolled for 6 years were carried out by eight GCP labs.
The trial results demonstrated that Qinbai was highly effective
in treating M. pneumoniae without developing any adverse side
effect or drug resistance, which is unpublished data. Early exper-
iments also confirmed that Qinbai had high anti-M. pneumoniae
pharmacodynamics in vitro with a MIC of 100μg/ml. Qinbai
can improve EGF expression in epithelial cells and prevent the
damage to lung organizational structures caused by M. pneumo-
niae, leading to epithelial restoration and cilia regeneration (Meng
et al., 2012). Further acute toxicity and chronic toxicity experi-
ments showed that Qinbai was safe. Therefore, Qinbai became an
alternative option besides Macrolides in treating M. pneumoniae
infection.
Qinbai main constituents, Scutellaria baicalensis and
Platycodon grandiflorum, have been used to treat thousands of
patients in China. Platycodon grandiflorum was widely used to
treat inflammatory diseases such as bronchitis, tonsillitis, laryn-
gitis, and suppurative dermatitis. Platycodin D is extracted from
the root of Platycodon grandiflorum and is one of monomers
of Qinbaiqingfei pellets, while Platycodon grandiflorum has
been widely used as Traditional Chinese Medicine for thousands
years in treating various diseases. Recent study demonstrated
that platycodin D enhanced anti-cancer activities of doxoru-
bicin in both MCF-7 and MDA-MB-231 cell lines (Tang et al.,
2014), induced cell apoptosis, and inhibited cell adhesion,
migration and invasion in the hepatocellular carcinoma cells
(Li et al., 2014). It could relieve atopic dermatitis-like skin
symptoms by suppressing NF-κB and STAT1 and inhibiting
TNF-α/IFN-γ-induced TARC expression (Choi et al., 2014).
In addition, platycodin D could inhibit the production of
IL-6 and TNF- α to cure rheumatoid arthritis (Kwon et al.,
2014). Platycodin D was also spermicidal, contraceptive (Lu
et al., 2013), and anti-atherosclerotic (Wu et al., 2012). It has
also been reported that platycodin D could be an alternative
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treatment of obesity by down-regulating lipid accumulation
(Lee et al., 2012) and that platycodin D was identified as active
component with anti-HCV activity (Kim et al., 2013). However,
there was no report on the anti-M. pneumoniae property of
Platycodin D.
This study was designed to investigate the anti-M. pneumoniae
effects of Platycodin D and the related cell growth recovery after
anti-M. pneumoniae treatment in the infected model organisms.
M. pneumoniae–infected BALB/c mice and A549 type II pneumo-
cytes from human-derived epithelial cell line were used to prove
that Platycodin D could not only inhibit M. pneumoniae in vitro
but also show the same effect in vivo. Our study presented a
comprehensive view of Platycodin D, which would illuminate the




This study was carried out in strict accordance with the Guide
for the Care and Use of Laboratory Animals of Heilongjiang
Province. All research protocols were approved by the Animal
Experiment Ethic Committee in Heilongjiang Academy of
ChineseMedicine Sciences (Permit Number: [2011] 93). All surg-
eries were performed under sodium pentobarbital anesthesia, and
all efforts were made to minimize suffering. Mice were humanely
sacrificed via cervical dislocation.
MATERIALS
The PPLO Broth was purchased from BD, USA. Fresh yeasts
were purchased from Angel Yeast Company, China. The RPMI
1640 media and Fetal Bovine Serum (FBS) were purchased from
Hyclone, USA. Quantitative Diagnostic Kit for M. pneumoniae
DNA was purchased from Da-An Gene, China. The Trizol was
purchased from Ambion, USA. The 6-well plates were purchased
from Corning, USA. Platycodin D was purchased from Chengdu
Herbpurify Co. Ltd, China
PLATYCODIN D PREPARATION
Platycodin D was purchased from Chengdu Herbpurify Co. Ltd
(20mg, J-013-120321, HPLC ≥ 98%). The 10mg/ml Platycodin
D solution was prepared with ultra-pure water and was stored
at −20◦C for late use. At the time of use, the stock solution
was diluted with PPLO media supplemented with 20% fetal calf
serum.
M. PNEUMONIAE AND CELL CULTURE
M. pneumoniae (ATCC 15531) purchased from American Type
Culture Collection was grown at 37◦C in PPLO–yeast-extract–
glucose-penicillinmedia supplemented with 20% fetal calf serum.
106 ccu M. pneumoniae were used in the following experiments.
A549 cells were cultured in 1640 medium with 10% fetal calf
serum and 5% CO2 at 37◦C, and were subcultured every 3–4 days
by trypsinization.
CCU
Color Change Unit (CCU): Tenfold dilution method was used to
measureM. pneumoniae concentration in the original media. 1ml
medium containing 100 ul M. pneumoniae went through Tenfold
dilutions with 10 bottles. The samples were incubated at 37◦C for
1 week. One ccu is defined as the reciprocal of the first dilution
that showed a stable color change.
CELL INFECTION
106 ccu M. pneumoniae suspensions were used to infect 105
A549 cells for 4 h before media supernatant was removed with
unbound M. pneumoniae. Cells were divided into control (non-
infected cells), model (infected cells without treatment) and
treated groups (infected cells treated with 16 ug/ml or 32 ug/ml
Platycodin D for 3d).M. pneumoniaeDNAwas quantified in each
group.
ANIMAL INFECTION
BALB/c mice (weighted 20 ± 1 g) were purchased from
Laboratory Animals Center of Jilin University and were kept in
GLP room at 25◦C with 60% humidity. The mice were randomly
divided into three groups, control group (non-infected mice),
model group (infected mice treated with saline), and experimen-
tal group (infected mice treated with Platycodin D) (10 mice for
each group). Themodel and experimental groups were inoculated
with 20 ul 106 ccuM. pneumoniae for 3d before the mice in exper-
imental group were gavaged daily with 5mg/kg.d (low dose) or
10mg/kg.d (high dose) Platycodin D for 6d, while mice in con-
trol and model groups were given equal volume of saline. Same
amount of lung homogenate were collected from each group for
M. pneumoniae DNA quantification.
Preparation of High-dose Platycodin D on the mice
(10mg/kg.d): 5.1 g Platycodon grandiflorum/d (conversion of
the Qinbai dose used in human treatment) × 1.5% (extraction
percentage) ×0.0026 × 50.
Preparation of Low-dose PlatycodinD (5mg/kg.d): 1/2 High
dose Platycodin D.
MINIMAL INHIBITION CONCENTRATION (MIC)
Double dilution methods were used to determine the MIC of
Platycodin D. If Platycodin D concentration reaches the MIC
level, M. pneumoniae metabolism will be inhibited, resulting
in no change of color in the sample. 1ml medium contain-
ing 100 ul 106 ccu M. pneumoniae was treated with 128 ug/ml
Platycodin D initially and the mixtures went through double
dilutions with Platycodin D concentration ranging from 128 to
2 ug/ml. After the color in the control media turned from red
to yellow, the resulted mixtures were collected and were ana-
lyzed with real-time quantitative PCR (BIOER, Line Gene 9600,
China).
MTT
Cell proliferation was assessed by the MTT 3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay.
Infected cells in 96 well plate (4 × 103cells/well) were treated with
16μg/ml or 32μg/ml Platycodin D for 3 days, and non-infected
cells were treated with 2–512μg/ml Platycodin D for 3 days. The
resulted cells were then incubated with 0.5%MTT reagent for 4 h
at 37◦C before they were treated with 150 ul of DMSO for 10min
(Twentyman and Luscombe, 1987). Absorbance at 490 nm was
measured using a Tecan Infinite M200 PRO enzyme-labeled
instrument.
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REAL-TIME QUANTITATIVE PCR
Quantitative Diagnostic Kit for M. pneumoniae includes a DNA
extraction kit and an amplification kit (probe and primers). The
measurement was carried out according to the manufacturer’s
protocol. Briefly, lung homogenate or cells of the 3 wells and DNA
extract buffer were mixed in 100◦C water for 10min before the
mixture was centrifuged at 12000 rpm for 5min. The supernatant
was used for the following PCR reaction. The PCR reaction con-
ditions were as follows: initial denaturation at 93◦C for 2min,
followed by 10 cycles of 93◦C for 45 s and 55◦C for 1min, and
another 30 cycles of 93◦C for 30 s and 55◦C for 45 s.
SURVIVING CELLS COUNT
The surviving cells were measured for control, model group
and experimental groups (16μg/ml and 32μg/ml Platycodin D
groups respectively). An equal volume of Trypan blue dyes was
added to each well and cells were counted by cell count cham-
ber under the light microscope. Cell concentration was calculated
with the following formula: cell amount/ml =∑ cell counted in
4 large squares/4 × dilution factor × 104.
HISTOPATHOLOGY EVALUATION OF THE LUNG TISSUES AND CELLS
A549 cells were fixed with 10% formalin for 48 h before they
were stained with hematoxylin and eosin(HE). Fixed lung tissues
were embedded in paraffin and then were cut into 5μm slides.
Tissue samples were stained with HE after they were hydrated
with xylene and alcohol. Microscopic analyses were done using
Olympus microscopy (BX41-DP72) at 20X magnification. The
data were presented in a scoring system for histopathology
inflammatory as described previously (Cimolai et al., 1992).
STATISTICAL ANALYSIS
All above experiments were carried out in duplicates. Data were
presented as mean ± SD and were analyzed with paired t-tests.
P < 0.05 was considered statistically significant.
RESULTS
CYTOTOXICITY EFFECT OF PLATYCODIN D
MTT method was used to investigate the cytotoxicity effect of
Platycodin D. Cells were divided into control and tested groups,
with tested groups treated with 2–512μg/ml Platycodin D for
3 days. Results showed that Platycodin D wasn’t cytotoxic to
cell growth with the concentration in the range of 2–512μg/ml.
Minor change on the cell inhibition ratio was observed with
Platycodin D at 2–128μg/ml, but this cell inhibition difference
between control and tested groups was not statistically significant
(P > 0.05) (Figure 1).
THE ANTI-M. PNEUMONIAE PROPERTY OF PLATYCODIN D
MIC
M. pneumoniae were incubated at 37◦C with Platycodin D rang-
ing from 2 to 128μg/ml (with serial double dilutions). Resulted
FIGURE 1 | Cytotoxicity effect of Platycodin D monitored by MTT
assay. The growth of A549 cells in 96-well plate was assessed
according to the absorbance at 490 nm. (A) Cell images under
microscopy. (B) MTT assay. (C) Statistical Analysis. Experiments
were repeated twice. Data were presented as mean ± SD,
P > 0.05.
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FIGURE 2 | In vitro activity of Platycodin D against M. pneumoniae. (A) The antimicrobial tests with the tube double dilution method. (B) Statistical
Analysis of the the antimicrobial tests with Real-time quantitative PCR method.
FIGURE 3 | Real-Time PCR analysis of M. pneumoniae amount in A549
cells. Infected cells were treated with 16μg/ml or 32μg/ml of Platycodin D
for 3 d. DNA levels were compared for those two groups. Experiments
were repeated twice. Data were presented as mean ± SD, *p < 0.05.
mixtures were not collected until the red phenol turned into yel-
low in the control group. Gene expression was then measured
with real-time quantitative PCR. Absolute standard curves of the
Quantitative Diagnostic Kit for M. pneumoniae DNA are a linear
range of 103–108 genome copies/ml. When bacteria concentra-
tion is more than 108 genome copies/ml, quantification results
in 1010 copies/ml. Platycodin D had a reasonably good inhibi-
tion capability against M. pneumoniae, with a MIC of 16μg/ml
(Figure 2). Our results suggested that Platycodin D would be a
potential candidate forM. pneumoniae treatment.
Inhibition effects of Platycodin D on infected A549 cells
A549 cells in different groups infected with M. pneumoniae and
treated with Platycodin D were harvested and analyzed for the
anti-M. pneumoniae effect of Platycodin D. Our results indicated
that M. pneumoniae count less in the group treated with high
dosage of Platycodin D than in the group treated with low dosage
of Platycodin D compared to model (Figure 3).
Inhibition effect of Platycodin D in infected BALB/c mice
Real-Time PCRwas used to analyze DNA levels ofM. pneumoniae
in BALB/c mice treated with low or high dosage of Platycodin
D. Our results indicated that the amount of M. pneumoniae
dropped in both treated groups compared to the model with
the high-dose-Platycodin-D -treated group dropping the most
(Figure 4).
FIGURE 4 | Real-Time PCR analysis of M. pneumoniae amount in the
mice. Infected mice were gavaged once daily with 5mg/kg/d or 10mg/kg/d
of Platycodin D for 6 d. DNA levels were compared between these three
groups. Experiments were repeated twice. Data were presented as
mean ± SD, ∗p < 0.05.
INFLUENCE ON THE CELL GROWTH AFTER ANTI-M. PNEUMONIAE
TREATMENT
Surviving cells quantification in the infected A549 cell
The cell amounts were measured with the Trypan Blue stain
method, in addition to the cells imaging method under
microscopy at 20Xmagnification. The cell count increased mean-
ingfully in both high-dose (32μg/ml) and low-dose (16μg/ml)
Platycodin D groups compared to the model group (Figure 5).
Viability of infected A549 cells treated with Platycodin D
MTT assay was used to investigate the effect of Platycodin D on
the growth of M. pneumoniae-infected A549 cells. Cell prolifer-
ation results showed that treated groups had higher cell growth
than the model group did, with the high dose group with the
highest cell growth (Figure 6).
HE staining in A549 cells
Infected A549 cell HE staining results showed that cell density
dropped while apoptosis increased in the model. In addition,
cell hydropic degeneration, pale cytoplasm, intracytoplasmic vac-
uoles, and indistinct cytoplasmic borders were also observed in
the model. There was a slightly decrease of the cell density and
increase in apoptosis and cell hydropic degeneration in the low
dose groupwhile high dose groupwas similar to the control group
(Figure 7).
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FIGURE 5 | Surviving cells quantified with images taken under the light microscope. (A) Cell images under microscopy. (B) Surviving cells quantified by
cell counting chamber. Experiments were repeated twice. Data were presented as mean ± SD, ∗p < 0.05.
FIGURE 6 | A549 cell growth monitored by MTT assays. Cells treated
with 16μg/ml or 32μg/ml Platycodin D for 3d, compared with the control
group. The growth of M. pneumoniae-infected A549 cells in 96-well plate
was assessed based on the absorbance at 490 nm. Experiments were
repeated twice. Data were presented as mean ± SD, ∗P < 0.05.
HE staining in the lung tissue
HE staining on lung fractions of these BALB/c mice was car-
ried out to assess the changes in morphology. HE staining score
was higher in the model group than in the treated groups.
Desquamating of the epithelial cells, thickening of the peribron-
chovascular interstitium, collapse of alveolar walls, and conges-
tion of capillaries with excess red blood cells were observed in the
model group. In the low dose group, there were some desqua-
mating of the epithelial cells, collapse of alveolar walls and the
congestion of capillaries with excess red blood cells, but the
situation was much lighter in the high dose group (Figure 8).
DISCUSSION
Platycodon grandiflorum, one of top 40 Chinese medicines
in annual sales, has been widely used to treat various dis-
eases in Traditional Chinese Medicine for thousands of years
for its immunomodulatory, anti-inflammatory, expectorant, and
antioxidant capabilities (Song and Qi, 2006). Its main active
ingredients include triterpenoid saponin, flavanoid, phenolic
compounds and fatty acids. Its monomers include Platycodin A,
B, C, D, D2, D3, and Polygalacin D, D2 (Jin, 2007). According
to some recent studies, Platycodin D showed bioactivity in
anticancer (Chun et al., 2013), antirheumatoid arthritis and
immunomodulatory (Kwon et al., 2014), and antiobesity (Lee
et al., 2012). It was also reported that Platycodin D could reg-
ulate the production and secretion of airway mucin to prevent
inflammatory diseases, which might explain the traditional use of
Platycodon grandiflorum as expectorants in treating inflamma-
tory pulmonary diseases (Ryu et al., 2014).
However, the anti-M. pneumoniae property of Platycodin D
remained to be explained. Our study presented the first com-
plete description of such activities of Platycodin D. Firstly, in this
study, the cytotoxicity effect of the Platycodin D was measured
by MTT to prove its safety and test showed that Platycodin D
wasn’t cytotoxic to cell growth up to 512μg/ml. Minor change
on the cell inhibition ratio was observed with Platycodin D at 2–
128μg/ml, but this cell inhibition difference between control and
tested groups was not statistically significant. The results of the
cell images under microscopy further showed that there wasn’t
obvious difference between the control and treated groups in
terms of morphology and amount. Secondly, MIC of Platycodin
D was measured for anti- M. pneumoniae capability, with the
actual MIC of the Platycodin D determined as 16μg/ml. Qinbai is
a compound that includes 6 constituents and auxiliary material.
Platycodon D concentration in the 100μg/ml Qinbai is far lower
than 16 ug/ml. Therefore, our study suggests that the combina-
tion of the different constituents of Qinbai causes inhibition of
M. pneumoniae proliferation and promotion of cell growth after
anti-M. pneumoniae treatment.
In addition, DNA levels of M. pneumoniae were measured in
both infected cultured cells and animals following the treatment
with a low or high dose of Platycodin D. Until now, methods
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FIGURE 7 | Results of pathological changes in M. pneumoniae-infected A549 cells. Cells treated with 16μg/ml or 32μg/ml Platycodin D for 3d, compared
with the control group. Cells were imaged at 40X. Experiments were repeated twice.
FIGURE 8 | Pathological changes of lung tissues in
M. pneumoniae-infected BALB/C mice. Histopathological changes of the
slices on a scale from 0 (no change) to 26 (maximum inflammation) based on
peribronchiolitis, perivasculitis, interstitial pneumonitis, and alveolitis. Mice
treated with 5mg/kg/d (low dose group) or 10mg/kg/d (high dose group)
Platycodin D for 6d, compared with the control. Slices were imaged at 20X.
Experiments were repeated twice. Data were presented as mean ± SD,
∗p < 0.05.
used in monitoring M. pneumoniae concentration in cells or tis-
sue included immunofluorescence and PCR DNA test methods.
Among those methods, PCR was the most used in research labo-
ratories (Ossewaarde et al., 1996; Tang et al., 2000). In our study,
DNA of M. pneumoniae was measured with the Real-Time PCR.
Our results showed that M. pneumoniae DNA level was higher in
the model group than in the treated groups (low-dose and high-
dose groups). M. pneumoniae amount dropped in the treated
groups when compared to the model group in vitro. In infected
animal model, same results were observed with mycoplasma
higher in the model group than in the low dose and high
dose groups. The above results both in vitro and in vivo fur-
ther confirmed that Platycodin D had an inhibition effect on
M. pneumoniae proliferation.
The second purpose of this study was to investigate the effects
of Platycodin D on the growth of infected A549 cells and lung
tissues after anti-M. pneumoniae treatment. MTT was used to
measure the cell growth after anti-M. pneumoniae treatment and
results showed that the treated group had a much better cell pro-
liferation than the model group. HE staining is usually used to
observe the cell or tissue damages. Damages of lung tissue such
as desquamating of epithelial cells, collapse of alveolar walls and
the congestion of capillaries, could be displayed clearly by this
method. Changes of cell morphology including apoptosis, cell
hydropic degeneration, and indistinct cytoplasmic borders could
also be measured in this way. Morphological changes of cells and
lungs for different groups were presented in Figures 5, 6. The
results showed that the treated group had a much better cell or
tissue proliferation than the model group. Trypan Blue stain and
MTT analyses yielded the same results.
Our studies demonstrated that Platycodin D not only inhib-
ited M. pneumoniae proliferation and promoted cell growth
after anti-M. pneumoniae treatment in vitro but also showed the
same effects in vivo. Our work provided a solid foundation for
future work in exploring mechanisms of this Traditional Chinese
Medicine.
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